Spike glycoprotein, S glycoprotein receptor binding domain, S-RBD, LY3832479, LY-CoV-016, Etesevimab

SARS-CoV-2

CPC516B pdf (datasheet)

100 µg

Please Inquire

1.0 mg/ml

New catalog number DVV00306

Recombinant Human anti-SARS-CoV-2 Spike Protein Receptor Binding domain, Etesevimab (Clone CB6, JS016), is expressed in XtenCHO. The monoclonal antibody JS016, was obtained from a B lymphocyte of a COVID-19 survivor, and binds with high-affinity to the receptor-binding domain within the S1 subunit of the SARS-CoV-2 spike protein, thus blocking the binding between the virus and the cell surface receptor angiotensin-converting enzyme 2 (ACE2) The spike glycoprotein is found on the outside of the virus particle and gives coronavirus viruses their crown-like appearance. Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

Spike glycoprotein

P0DTC2

Recognizes SARS-CoV-2 Spike-NTD protein

Human

Derived from a B lymphocyte of a convalescing COVID-19 patient

IgG

CB6, JS016, LY-CoV-016, LY3832479

Sterile-filtered PBS, pH 7.5 preservative free.

Protein A affinity chromatography

ELISA, FS , Neutralizing , WB

ELISA: suggested dilution 1:5,000 - 1:10,000
Western blot: suggested dilution 1:1,000 - 1:2,000

Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare working aliquots of undiluted product and store -20°C to -80°C.